Modeling population immunity to support efforts to end the transmission of live polioviruses

Risk Analysis

Volumn 33, Issue 4, 2013, Pages 647-663

  Thompson, Kimberly M ^a,d   Pallansch, Mark A ^b   Tebbens, Radboud J Duintjer ^a   Wassilak, Steve G ^c   Cochi, Stephen L ^c  

^a Kid Risk Inc   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

Immunity; Poliovirus; Vaccine

Indexed keywords

CASE-BASED APPROACH; CONCEPTUAL APPROACHES; DISEASE OUTBREAKS; IMMUNITY; MODELING APPROACH; POLICY MAKERS; POLIOVIRUS; SURVEILLANCE SYSTEMS;

RISK MANAGEMENT;

VACCINES;

CONCEPTUAL FRAMEWORK; DISEASE SPREAD; DISEASE TRANSMISSION; HEALTH RISK; IMMUNITY; PUBLIC HEALTH; RISK ASSESSMENT; SYMPTOM; VACCINE; VIRUS;

ARTICLE; DISEASE TRANSMISSION; HUMAN; IMMUNOLOGY; POLIOMYELITIS; POLIOMYELITIS VIRUS; RISK MANAGEMENT; THEORETICAL MODEL;

HUMANS; MODELS, THEORETICAL; POLIOMYELITIS; POLIOVIRUS; RISK MANAGEMENT;

POLIOVIRUS;

EID: 84875933790     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/j.1539-6924.2012.01891.x     Document Type: Article

References (75)

1. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim J-H, Cochi SL. Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Analysis, 2013; 33(4):516-543.
2. World Health Assembly. Poliomyelitis: Mechanism for Management of Potential Risks to Eradication (Resolution 61.1). Geneva: World Health Organization, 2008. Available at: http://www.polioeradication.org/content/general/WHA61_Resolution_English.pdf, Accessed August 29, 2012.
3. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander JP, Jr., Jafari H, Cochi SL. The risks, costs, and benefits of possible future global policies for managing polioviruses. American Journal of Public Health, 2008; 98(7):1322-1330.
4. Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation. Medscape Journal of Medicine, 2008; 10(8):190.
5. de Gourville EM, Sangrujee N, Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Global surveillance and the value of information: The case of the global polio laboratory network. Risk Analysis, 2006; 26(6):1557-1569.
6. Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: An economic analysis. Lancet, 2007; 369(9570):1363-1371.
7. Thompson KM, Duintjer Tebbens RJ. Using system dynamics to develop policies that matter: Global management of poliomyelitis and beyond. System Dynamics Review, 2008; 24(4):433-449.
8. World Health Organization. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Weekly Epidemiological Record, 2010; 85:213-228.
9. Bernier RH. Some observations on poliomyelitis lameness surveys. Reviews of Infectious Diseases, 1984; 6(Suppl 2):S371-S375.
10. Nathanson N, Kew OM. From emergence to eradication: The epidemiology of poliomyelitis deconstructed. American Journal of Epidemiology, 2010; 172(11):1213-1229.
11. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. American Journal of Epidemiology, 2005; 162(4):358-372.
12. Simons E, Mort M, Dabbagh A, Strebel P, Wolfson L. Strategic planning for measles control: Using data to inform optimal vaccination strategies. Journal of Infectious Diseases, 2011; 204(Suppl 1):S28-S34.
13. Gay NJ. Modeling measles, mumps, and rubella: Implications for the design of vaccination programs. Infection Control and Hospital Epidemiology, 1998; 19(8):570-573.
14. Bauch CT, Szusz E, Garrison LP. Scheduling of measles vaccination in low-income countries: Projections of a dynamic model. Vaccine, 2009; 27(31):4090-4098.
15. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim J-H, Thompson KM. Expert review on poliovirus immunity and transmission. Risk Analysis, 2013; 33(4):544-605.
16. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim J-H, Thompson KM. Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. Risk Analysis, 2013; 33(4):606-646.
17. Abbas AK, Lichtman AH. Basic Immunology: Functions and Disorders of the Immune System. 2nd ed. Philadelphia, PA: Saunders, 2006.
18. Modlin JF. Coxsackieviruses, echoviruses, and newer enteroviruses. Pp. 1904-1919 in Mandell GL, Bennett JE, Dolin R (eds). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Philadelphia, PA: Churchill-Livingstone, 2000.
19. Ogra PL. Mucosal immune response to poliovirus vaccines in childhood. Reviews of Infectious Diseases, 1984;6(Suppl 2):S361-S368.
20. Expanded Programme on Immunization. Report of a WHO informal consultation on polio neutralizing antibody assays, Nashville, 5-6 December 1991. Geneva: World Health Organization, 1991. Report No.: WHO/EPI/RD/91.3 Rev 1.
21. Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, Hadler SC. Defining surrogate serologic tests with respect to predicting protecive vaccine efficacy: Poliovirus vaccination. Pp. 289-299 in William JC, Goldenthal KL, Burns DL, Lewis BPJ (eds). Combined Vaccines and Simultaneous Administration. Current Issues and Perspectives. New York: New York Academy of Sciences, 1995.
22. Halsey N, Galazka A. The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. Bulletin of the World Health Organization, 1985; 63(6):1151-1169.
23. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. Pp. 631-686 in Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines. 5th ed. Philadelphia, PA: Saunders Elsevier, 2008.
24. Pujol JM, Eisenberg JE, Haas CN, Koopman JS. The effect of ongoing exposure dynamics in dose response relationships. PLoS Computational Biology, 2009; 5(6):e1000399. DOI: 10.1371/journal.pcbi.1000399.
25. Henry JL, Jaikaran ES, Mason PJ, Barnes JM, Beale AJ. A study of polio vaccination in infancy: Excretion following challenge with live virus by children given killed or living poliovaccine. Journal of Hygiene Cambridge, 1966; 64:105-120.
26. Onorato IM, Modlin JF, McBean MA, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. Journal of Infectious Diseases, 1991; 163:1-6.
27. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, Strebel PM, Cono J, Wharton M, Orenstein WA, Sutter RW. Vaccine policy changes and epidemiology of poliomyelitis in the United States. Journal of the American Medical Association, 2004; 292(14):1696-1701.
28. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clinical Infectious Diseases, 1992; 14:568-579.
29. Chen RT, Hausinger S, Dajani AS, Hanfling M, Baughman AL, Pallansch MA, Patriarca PA. Seroprevalence of antibody against poliovirus in inner-city preschool children. Journal of the American Medical Association, 1996; 275(21):1639-1645.
30. Más Lago P, Bravo JR, Andrus JK, Comellas MM, Galindo MA, de Quadros CA, Bell E. Lesson from Cuba: Mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bulletin of the World Health Organization, 1994; 72(2):221-225.
31. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: Results of a randomized trial in the Gambia, Oman, and Thailand. WHO collaborative study group on oral and inactivated poliovirus vaccines. Bulletin of the World Health Organization, 1996; 74(3):253-268.
32. Benyesh-Melnick M, Melnick JL, Rawls WE, Wimberly I, Barrera Ora J, Ben-Porath E, Rennick V. Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. American Journal of Epidemiology, 1967; 86(1):112-136.
33. Gelfand HM, Potash L, Leblanc DR, Fox JP. Intrafamilial and interfamilial spread of living vaccine strains of polioviruses. Journal of the American Medical Association, 1959; 170(17):2039-2048.
34. Kew OM, Sutter RW, de Gourville E, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annual Review of Microbiology, 2005; 59:587-635.
35. Plotkin SA, Vidor E. Poliovirus vaccine - inactivated. Pp. 605-630 in Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines. 5th ed. Philadelphia, PA: Saunders Elsevier, 2008.
36. Fiore L, Plebani A, Buttinelli G, Fiore S, Donati V, Marturano J, Soresina A, Martire B, Azzari C, Nigro G, Cardinale F, Trizzino A, Pignata C, Alvisi P, Anastasio E, Bossi G, Ugazio AG. Search for poliovirus long-term excretors among patients affected by agammaglobulinemia. Clinical Immunology, 2004; 111(1):98-102.
37. Halsey NA, Pinto J, Espinosa-Rosales F, Faure-Fontenla M, da Silva EE, Kahn AA, ADB W, Minor PD, Dunn G, Asturia E, Hussain H, Pallansch MA, Kew OM, Winkelstein J, Sutter RW, the Polio Project Team. Search for polio virus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil and the United Kingdom. Bulletin of the World Health Organization, 2004; 82(1):3-8.
38. Khetsuriani N, Prevots DR, Quick L, Elder ME, Pallansch MA, Kew OM, Sutter RW. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. Journal of Infectious Diseases, 2003; 188:1845-1852.
39. National Research Council. Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. Washington, DC: National Academy Press, 2006.
40. Hennessey KA, Lago H, Diomande F, Akoua-Koffi C, Cáceres VM, Pallansch MA, Kew OM, Nolan M, Zuber PL. Poliovirus vaccine shedding among persons with HIV in Abidjan, Cote d'Ivoire. Journal of Infectious Diseases, 2005; 192(12):2124-2128.
41. The Cuba IPV Study Collaborative Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. New England Journal of Medicine, 2007; 356(15):1536-1544.
42. Melnick JL. Poliovirus and other enteroviruses. Pp. 583-663 in Evans AS, Kaslow RA (eds). Viral Infections of Humans: Epidemiology and Control. 4th ed. New York: Plenum Medical, 1997.
43. Glezen WP, Lamb GA, Belden EA, Chin TD. Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. American Journal of Epidemiology, 1966; 83(2):224-237.
44. Fine PEM. Herd immunity: History, theory, practice. Epidemiologic Reviews, 1993; 15(2):265-302.
45. Thompson KM, Wallace GS, Duintjer Tebbens RJ, Smith PH, Barskey AE, Pallansch MA, Gallagher KM, Alexander JP, Armstrong GL, Cochi SL, Wassilak SG. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Reports, 2012; 127(1):23-37.
46. Grassly NC, Wenger J, Durrani S, Bahl S, Deshpande JM, Sutter RW, Heymann DL, Aylward RB. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: A case-control study. Lancet, 2007; 369(9570):1356-1362.
47. Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Abanida EA, Koleosho-Adelekan T, Grassly NC. Effectiveness of immunization against paralytic poliomyelitis in Nigeria. New England Journal of Medicine, 2008; 359(16):1666-1674.
48. O'Reilly KM, Chauvin C, Aylward RB, Maher C, Okiror S, Wolff C, Nshmirimana D, Donnelly CA, Grassly NC. A statistical model of the international spread of wild poliovirus in Africa used to predict and prevent outbreaks. PLoS Medicine, 2011; 8(10):e1001109.
49. Prevots DR, Ciofi degli Atti ML, Sallabanda A, Diamanti E, Aylward RB, Kakariqqi E, Fiore L, Ylli A, van der Avoort HG, Sutter RW, Tozzi AE, Panei P, Schinaia N, Genovese D, Oblapenko G, Greco D, Wassilak SG. Outbreak of paralytic poliomyelitis in Albania, 1996: High attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clinical Infectious Diseases, 1998; 26(2):419-425.
50. World Health Organization. Outbreak news. Poliomyelitis, Namibia. Weekly Epidemiological Record, 2006; 81(24):238.
51. World Health Organization. Outbreak news-Outbreak of poliomyelitis, Republic of the Congo, September 2010-February 2011. Weekly Epidemiological Record, 2011; 86(15):141-142.
52. Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: Perspectives from modeling and prerequisites for OPV cessation. Expert Reviews of Vaccines, 2012; 11(4):449-459.
53. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Analysis, 2013; 33(4):703-749.
54. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. New York: Oxford University Press, 1991.
55. World Bank. Country Classification, 2009. Available at: http://go.worldbank.org/K2CKM78CC0, Accessed on June 13, 2009.
56. UN Population Division. World Population Prospects, The 2010 Revision 2010. Available at: http://esa.un.org/wpp/unpp/panel_population.htm, Accessed on August 31, 2012.
57. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review. Reviews of Infectious Diseases, 1991; 13:926-939.
58. Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: Implications for the global poliomyelitis eradication initiative. American Journal of Epidemiology, 1999; 150(10):1001-1021.
59. Fine PEM, Carneiro IAM. Transmissibility and Persistence of Oral Poliovirus Vaccine Viruses: Implications for the Global Poliomyelitis Eradication Initiative. London: Infectious Disease Epidemiology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene, 1998.
60. Fine PEM, Clarkson JA. Individual versus public priorities in the determination of optimal vaccination policies. American Journal of Epidemiology, 1986; 124(6):1012-1020.
61. Thompson KM, Duintjer Tebbens RJ. Economic evaluation of the benefits and costs of disease elimination and eradication initiatives. Pp. 115-130 in Cochi SL, Dowdle WR (eds). Disease Eradication in the 21st Century: Implications for Global Health. Cambridge, MA: MIT Press, 2011.
62. Thompson KM, Duintjer Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Analysis, 2006; 26(6):1423-1440.
63. Duintjer Tebbens RJ, Thompson KM. Priority shifting and the dynamics of managing eradicable infectious disease. Management Science, 2009; 55(4):650-663.
64. World Health Organization, 2010. Global Polio Eradication Initiative-Wild Poliovirus List 2000-2010. Available at: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpolioviruslist.aspx, Accessed on November 12, 2010.
65. MacDonald N, Hébert PC. Polio outbreak in Tajikistan is cause for alarm. Canadian Medical Association Journal, 2010; 182(10):1013. DOI: 10.1503/cmaj.100831.
66. World Health Organization Regional Office for Europe, 2010. WHO Epidemiological Brief: Tajikistan Polio Outbreak and Regional Response. Available at: http://www.euro.who.int/__data/assets/pdf_file/0019/118342/EPI_TJK_Issue3.pdf, Accessed on July 27, 2010.
67. Moscrop A. Yemen embarks on its seventh round of polio immunisations. British Medical Journal, 2005; 331(7529):1358.
68. Estivariz CF, Watkins M, Handoko D, Rusipah R, Deshpande J, Rana BJ, Irawan E, Widhiastuti D, Pallansch MA, Thapa A, Imari S. A large vaccine-derived poliovirus outbreak on Madura Island-Indonesia, 2005. Journal of Infectious Diseases, 2008; 197(3):347-354.
69. Kew O, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, Garib Z, Andre J, Blackman E, Freeman CJ, Jorba J, Sutter R, Tambini G, Venczel L, Pedreira C, Laender F, Shimizu H, Yoneyama T, Miyamura T, van Der Avoort H, Oberste MS, Kilpatrick D, Cochi S, Pallansch M, de Quadros C. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science, 2002; 296(5566):356-359.
70. Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Mwanza M, Corander J, Garnier S, Chauvin C, Abanida E, Pate MA, Adu F, Baba M, Grassly NC. Implications of a circulating vaccine-derived poliovirus in Nigeria. New England Journal of Medicine, 2010; 326(25):2360-2369.
71. Aylward RB, Sutter RW, Heymann DL. OPV cessation-the final step to a "polio-free" world. Science, 2005; 310(5748):625-626.
72. World Health Organization. Polio Eradication Initiative. Cessation of Routine Oral Polio Vaccine (OPV) Use After Global Polio Eradication. Framework for National Policy Makers in OPV-Using Countries. Geneva, Switzerland: Report No.: WHO/POL/05.02, 2005.
73. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Aylward RB, Thompson KM. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis, 2006; 26(6):1471-1505.
74. Grassly NC, Jafari H, Bahl S, Durrani S, Wenger J, Sutter RW, Aylward RB. Asymptomatic wild-type poliovirus infection among children with previous oral poliovirus vaccination. Journal of Infectious Diseases, 2010; 10:1535-1543.
75. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Afghanistan and Pakistan, 2008. Morbidity and Mortality Weekly Report, 2009; 58(8):198-201.